Ernexa Therapeutics Inc. (ERNA) vs Lexaria Bioscience Corp. (LEXX)

A side-by-side comparison of Ernexa Therapeutics Inc. and Lexaria Bioscience Corp. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — ERNA vs LEXX

growth of $100 · dividends reinvested · last 6y
ERNA -100.0% (-79.5%/yr)LEXX -95.9% (-41.2%/yr)LEXX compounded faster over this window
Log scale — wide-divergence pair
0001101001k10kStart $10020222023202420252026$0$4
ERNA LEXX

ERNA vs LEXX: by the numbers

  • •LEXX is the larger company ($5M vs $4M market cap).
  • •Both run net losses; ERNA's is the smaller (0.00% vs -3985.58% net margin).

Metrics side by side

Valuation

MetricERNALEXX
P/S ratioN/A24.57
P/B ratio1.121.01

Profitability

MetricERNALEXX
Gross margin0.00%100.00%
Operating margin0.00%-1683.01%
Net margin0.00%-3985.58%
ROE-383.03%-163.18%
ROIC-346.94%-175.26%

Growth (annualized)

MetricERNALEXX
Revenue CAGR (5Y)N/A12.92%
Total return CAGR (5Y)-86.83%-50.86%

Frequently asked

How have ERNA and LEXX total returns compared?
Over the past 5 years, ERNA delivered -86.83% and LEXX delivered -50.86% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.